Blueprint Medicines (BPMC) and Its Competitors Head-To-Head Survey
Blueprint Medicines (NASDAQ: BPMC) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Blueprint Medicines to related companies based on the strength of its profitability, institutional ownership, dividends, analyst recommendations, valuation, earnings and risk.
Insider and Institutional Ownership
91.4% of Blueprint Medicines shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 3.4% of Blueprint Medicines shares are owned by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Blueprint Medicines and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Blueprint Medicines||$27.77 million||-$72.49 million||-21.35|
|Blueprint Medicines Competitors||$217.28 million||-$39.39 million||-67.54|
Blueprint Medicines’ competitors have higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Blueprint Medicines and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Blueprint Medicines Competitors||-3,232.46%||-524.26%||-40.73%|
Risk & Volatility
Blueprint Medicines has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Blueprint Medicines’ competitors have a beta of 1.52, meaning that their average stock price is 52% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Blueprint Medicines and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Blueprint Medicines Competitors||529||2438||6640||122||2.65|
Blueprint Medicines currently has a consensus target price of $70.47, indicating a potential downside of 3.23%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.67%. Given Blueprint Medicines’ competitors higher possible upside, analysts clearly believe Blueprint Medicines has less favorable growth aspects than its competitors.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.